Drug intelligence / Profile preview

BSC3302

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules
Administration: Ophthalmic

Overview

BSC3302 is a preclinical-stage small molecule inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1), being developed by BiSiChem. It is formulated as an eye drop for the treatment of various retinal diseases. RIPK1 is a key mediator of necroptosis and inflammation, processes implicated in the pathogenesis of retinal degeneration and other ocular disorders. By inhibiting RIPK1, BSC3302 aims to prevent cell death and reduce inflammatory responses in the retina.

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on BSC3302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC3302.

Explore the full profile